July 2004

NIH funds clinical trials of chromium picolinate

The Yale-Griffin Prevention Research Center (PRC), a collaboration between Griffin Hospital and the Yale School of Epidemiology and Public Health, announced the start of a double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium supplementation on blood glucose levels and endothelial function in people with pre-diabetes. The two-year pilot study is funded by a grant from the National Institutes of Health's (NIH) National Center for Complementary and Alternative Medicine (NCCAM).

"The aim of this clinical trial is to further explore the benefit of nutritional intervention with chromium picolinate, before pre-diabetes progresses into a chronic disease state," explains Dr. David Katz, director of the Yale-Griffin Prevention Research Center and principal investigator of the new study. "In pre-diabetes, pharmacotherapy may not yet be justified or acceptable for patients. Chromium has shown potential to serve as a safe and affordable adjunct nutritional therapy, as part of a preventive approach."

Pre-diabetes, also known as Impaired Glucose Tolerance (IGT), affects approximately 41 million Americans and is a pre-cursor to type 2 diabetes and cardiovascular disease. The American Diabetes Association (ADA) defines pre- diabetes as a condition in which blood sugar levels are higher than normal, but not high enough to be diagnosed as type 2 diabetes.

Source: Yale-Griffin Prevention Research Center

Industry News from:
Chiropractic News from: